Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Losartan
Drug ID BADD_D01322
Description Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension.[L7423] Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough.[L7423] When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or [hydrochlorothiazide].[L7423] Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide.[L7423,L7426] Patients taking losartan should have their renal function and potassium levels monitored.[L7423] Losartan was granted FDA approval on 14 April 1995.[L7423]
Indications and Usage Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension.[L7423] Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).[L7426]
Marketing Status approved
ATC Code C09CA01
DrugBank ID DB00678
KEGG ID D08146
MeSH ID D019808
PubChem ID 3961
TTD Drug ID D0DD0K
NDC Product Code 70010-741; 62207-742; 70010-742; 70010-743
UNII JMS50MPO89
Synonyms Losartan | 2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol | DuP-753 | DuP 753 | DuP753 | MK-954 | MK 954 | MK954 | Cozaar | Losartan Potassium | Potassium, Losartan | Losartan Monopotassium Salt | Monopotassium Salt, Losartan | Salt, Losartan Monopotassium
Chemical Information
Molecular Formula C22H23ClN6O
CAS Registry Number 114798-26-4
SMILES CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Musculoskeletal chest pain22.09.01.001; 15.03.04.0120.000039%
Cardiopulmonary failure22.02.06.004; 02.05.01.0040.000025%Not Available
Blood pressure inadequately controlled24.06.01.0070.000149%Not Available
Nasal odour22.04.03.0140.000010%Not Available
Fluid imbalance14.05.01.003--Not Available
Ear discomfort04.03.01.0050.000027%Not Available
Eye pruritus06.04.05.0060.000010%Not Available
Oral pruritus07.05.05.0020.000010%Not Available
Musculoskeletal stiffness15.03.05.027--Not Available
Epigastric discomfort07.01.02.0040.000034%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Organ failure08.01.03.0410.000010%Not Available
Inappropriate antidiuretic hormone secretion14.05.07.001; 05.03.03.0010.000010%Not Available
Skin swelling23.03.03.0390.000010%Not Available
Tracheal disorder22.04.07.0050.000010%Not Available
Mucosal discolouration08.01.06.0080.000010%Not Available
Cerebral disorder17.02.10.0170.000010%Not Available
Colitis microscopic07.08.01.0110.000055%Not Available
Paraesthesia oral07.05.05.035; 17.02.06.0080.000010%Not Available
Anxiety disorder19.06.01.002--Not Available
Toxic skin eruption12.03.01.073; 23.03.05.003; 10.01.01.0080.000035%Not Available
Ocular icterus09.01.01.007; 06.08.03.009; 01.06.04.0070.000022%Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Ventricular dysfunction02.04.02.0050.000010%Not Available
Angiopathy24.03.02.0070.000020%Not Available
Adverse event08.06.01.0100.000260%Not Available
Breast disorder21.05.04.004--Not Available
Feeding disorder19.09.01.003; 14.03.02.0030.000020%Not Available
Foetal disorder18.03.02.0010.000129%Not Available
Infarction24.04.02.0170.000020%Not Available
The 13th Page    First    Pre   13 14 15 16    Next   Last    Total 16 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene